1608 related articles for article (PubMed ID: 23647578)
1. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
2. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
3. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
7. Refractive changes after pharmacologic resolution of diabetic macular edema.
Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
[TBL] [Abstract][Full Text] [Related]
8. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
[TBL] [Abstract][Full Text] [Related]
9. Diabetic macular edema: fundus autofluorescence and functional correlations.
Vujosevic S; Casciano M; Pilotto E; Boccassini B; Varano M; Midena E
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):442-8. PubMed ID: 20720226
[TBL] [Abstract][Full Text] [Related]
10. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
[TBL] [Abstract][Full Text] [Related]
12. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
[TBL] [Abstract][Full Text] [Related]
13. HYPERREFLECTIVE RETINAL SPOTS AND VISUAL FUNCTION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CENTER-INVOLVING DIABETIC MACULAR EDEMA.
Vujosevic S; Berton M; Bini S; Casciano M; Cavarzeran F; Midena E
Retina; 2016 Jul; 36(7):1298-308. PubMed ID: 26689274
[TBL] [Abstract][Full Text] [Related]
14. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection.
Querques G; Bux AV; Martinelli D; Iaculli C; Del Curatolo MV; Delle Noci N
Retina; 2009 Oct; 29(9):1274-81. PubMed ID: 19696699
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
16. Correlation of fundus autofluorescence with spectral-domain optical coherence tomography and vision in diabetic macular edema.
Chung H; Park B; Shin HJ; Kim HC
Ophthalmology; 2012 May; 119(5):1056-65. PubMed ID: 22342014
[TBL] [Abstract][Full Text] [Related]
17. [Improvement of fixation in diabetic macular oedema patients under intravitreal ranibizumab treatment].
Seidensticker F; Reznicek L; Cserhati S; Liegl RG; Langer J; Wolf A; Kampik A; Ulbig M; Haritoglou C; Kernt M
Klin Monbl Augenheilkd; 2013 May; 230(5):524-9. PubMed ID: 23229224
[TBL] [Abstract][Full Text] [Related]
18. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
[TBL] [Abstract][Full Text] [Related]
20. Diabetic macular oedema quantified with spectral-domain optical coherence tomography--evaluation of boundary line artefacts and the effect on retinal thickness.
Hodzic-Hadzibegovic D; Sander BA; Lund-Andersen H
Acta Ophthalmol; 2015 Feb; 93(1):74-82. PubMed ID: 25042850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
